These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34415673)

  • 41. Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects.
    Trivedi A; Malik FI; Mackowski M; Hutton S; Aoki M; Abbasi S; Dutta S; Lee E
    Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):759-770. PubMed ID: 34415561
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator.
    Trivedi A; Oberoi RK; Mackowski M; Jafarinasabian P; Zhang H; Flach S; Simiens MA; Terminello B; Abbasi S; Dutta S; Lee E
    Biopharm Drug Dispos; 2021 Jul; 42(7):319-328. PubMed ID: 34087948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.
    Lee J; Rhee SJ; Lee S; Yu KS
    Drug Des Devel Ther; 2018; 12():787-794. PubMed ID: 29670335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling.
    Dong J; Prieto Garcia L; Huang Y; Tang W; Lundahl A; Elebring M; Ahlström C; Vildhede A; Sjögren E; Någård M
    Clin Pharmacol Ther; 2023 Oct; 114(4):825-835. PubMed ID: 37376792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
    Wang Q; Zheng M; Leil T
    CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters.
    Ho YL; Gorycki P; Ferron-Brady G; Martin P; Vlasakakis G
    Clin Transl Sci; 2024 Apr; 17(4):e13799. PubMed ID: 38634429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.
    Ou YC; Tang Z; Novotny W; Tawashi M; Li TK; Coleman HA; Sahasranaman S
    Br J Clin Pharmacol; 2021 Jul; 87(7):2926-2936. PubMed ID: 33336408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study.
    Grande E; Giovannini M; Marriere E; Pultar P; Quinlan M; Chen X; Rahmanzadeh G; Curigliano G; Cui X
    Br J Clin Pharmacol; 2021 Jul; 87(7):2867-2878. PubMed ID: 33300203
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
    Chang M; Bathena S; Christopher LJ; Shen H; Roy A
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):383-392. PubMed ID: 35147740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants.
    Wang L; Luan Y; Jia C; Xie X; Zhang Z; Xie X; Wang Q; Hu C; Xie F; Abdel-Moneim M; Hovsepian L; Zhao Z; Yang N; Hou J
    Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):51-62. PubMed ID: 36437383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.
    Kim Y; Yoon S; Choi Y; Yoon SH; Cho JY; Jang IJ; Yu KS; Chung JY
    Sci Rep; 2019 Dec; 9(1):19410. PubMed ID: 31857620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV.
    Moreira FL; Melli PPDS; Marques MP; Rocha A; Nardotto GHB; Duarte G; Lanchote VL
    J Clin Pharmacol; 2023 Feb; 63(2):219-227. PubMed ID: 36087110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers.
    Seong SJ; Ohk B; Kang WY; Gwon MR; Kim BK; Cho S; Yang DH; Lee HW; Yoon YR
    Adv Ther; 2019 Jul; 36(7):1642-1656. PubMed ID: 31119689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
    Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
    Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
    Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
    Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
    Gidal BE; Mintzer S; Schwab M; Schutz R; Kharidia J; Blum D; Grinnell T; Sunkaraneni S
    Epilepsy Res; 2017 Sep; 135():64-70. PubMed ID: 28624574
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects.
    Kim CH; An H; Kim SH; Shin D
    Drug Des Devel Ther; 2017; 11():3461-3469. PubMed ID: 29255347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan.
    Huh KY; Lee SW; Lee SB; Kim KT; Jang IJ; Lee S
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1290-1296. PubMed ID: 33647189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic and Safety Comparison of Fixed-Dose Combination of Cilostazol/Rosuvastatin (200 + 20 mg) Versus Concurrent Administration of the Separate Components in Healthy Adults.
    Kim JH; Hong JH; Jung JG; Jung WT; Nam KY; Roh JS; Choi YW; Bang J; Huh H; Lee HJ; Moon J; Kim J; Sunwoo J
    Clin Pharmacol Drug Dev; 2024 Aug; 13(8):842-851. PubMed ID: 38469999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
    Zhu T; Parker B; Wojtkowski T; Nishimura T; Garg JP; Han D; Fisniku O; Keirns J
    Clin Pharmacokinet; 2017 Jul; 56(7):747-757. PubMed ID: 27878567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.